Zealand Pharma taps Generate’s AI in obesity deal worth up to $1.2 billion

Zealand Pharma is betting that artificial intelligence can help it design the next wave of obesity drugs. The company announced a multi-target collaboration and license agreement with Generate Biomedicines on October 13, 2026. Total milestone payments could reach approximately $1.2 billion, plus tiered royalties on net sales. Generate’s shares rose about 5% in after-hours trading following the news. For a company that only went public in February, that is a warm welcome to big pharma partnerships. How the deal is structured Zealand will pay Generate a $30 million upfront fee. Beyond that, Generate is eligible for up to $35 million in preclinical milestone payments. These are cash rewards tied to hitting early research goals before any drug reaches a human trial. Generate would also collect tiered royalties based on net sales from the initial programs. The agreement covers two programs at the start. There is an option to add a third. Who does what Generate’s platform pairs generative design with high-throughput experimental validation. The company uses AI to propose new protein structures, then tests large numbers of them in the lab to see which ones actually work. The goal is to pi...